SKU: OPC-LEUGARD-225
Leugard 22.5mg Injection contains Leuprorelin 22.5mg and is a prescription hormonal medicine used under medical supervision for hormone-sensitive conditions including prostate cancer, endometriosis, uterine fibroids and certain cases of early puberty.
Leugard 22.5mg Injection contains Leuprorelin 22.5mg, a long-acting hormonal medicine belonging to the gonadotropin-releasing hormone (GnRH) agonist group. It is used under specialist medical supervision for hormone-sensitive conditions such as prostate cancer, endometriosis, uterine fibroids and certain cases of central precocious puberty.
Leuprorelin works by influencing the hormonal signals responsible for the production of sex hormones. With continued treatment, it can substantially reduce testosterone or estrogen production depending on the patient's condition.
Leugard is a prescription medicine and is administered by a qualified healthcare professional. The treatment schedule depends on the specific medical condition, treatment response and the doctor's prescribed regimen.
For more healthcare resources, visit our BuyCenforce Home.
Leugard 22.5mg Injection is a hormonal medicine containing Leuprorelin. It is designed to reduce the production of certain sex hormones that can contribute to the growth or symptoms of hormone-dependent conditions.
Leuprorelin initially stimulates GnRH receptors, but continued stimulation causes suppression of the hormonal pathway. This eventually lowers the production of testosterone in men and estrogen in women.
Leugard should only be administered according to a specialist's prescription. The medicine requires appropriate monitoring because hormonal changes can affect different body systems during treatment.
Leugard may be prescribed for hormone-dependent prostate cancer. By reducing testosterone levels, Leuprorelin can help slow the growth and progression of prostate cancer cells that depend on male hormones.
Leuprorelin may be used in the management of endometriosis by reducing estrogen stimulation. Lower estrogen levels can help reduce the hormonal stimulation of endometrial-like tissue and associated symptoms.
Leugard may be prescribed for selected patients with uterine fibroids. Reducing estrogen levels can help decrease fibroid-related symptoms and may reduce fibroid size during treatment.
Leuprorelin can be used under specialist supervision in certain children with central precocious puberty. It helps suppress premature activation of the reproductive hormone pathway and may slow early sexual development.
Leugard reduces the hormonal stimulation associated with several hormone-sensitive diseases, making it useful as part of specialist treatment plans.
In men, continued Leuprorelin treatment can significantly suppress testosterone production. This hormonal suppression is particularly important in hormone-sensitive prostate cancer.
In appropriate female patients, hormonal suppression can reduce estrogen stimulation and may help manage conditions such as endometriosis and uterine fibroids.
By lowering testosterone, Leugard can help slow the growth of hormone-dependent prostate cancer and may be used as part of a broader oncology treatment plan.
Hormonal suppression may reduce the stimulation of endometriosis-related tissue and can help improve symptoms such as pelvic pain and heavy menstrual discomfort in appropriate patients.
Lowering estrogen levels can reduce hormonal stimulation of uterine fibroids and may help with symptoms such as heavy menstrual bleeding and pelvic discomfort.
The active ingredient in Leugard 22.5mg Injection is:
Leuprorelin is also known as Leuprolide or Leuprorelin acetate and belongs to the GnRH agonist class of medicines.
Leugard contains Leuprorelin, a synthetic GnRH agonist. GnRH normally stimulates the pituitary gland to release hormones that control the production of sex hormones.
When Leuprorelin is given continuously, the hormonal pathway is initially stimulated but subsequently becomes suppressed. This decreases the release of luteinizing hormone and follicle-stimulating hormone.
As a result, testosterone production can fall significantly in men, while ovarian estrogen production can be suppressed in women. This hormonal effect is responsible for the therapeutic benefits of Leugard in several hormone-sensitive conditions.
Many prostate cancer cells depend on male hormones, particularly testosterone, for growth. Leuprorelin reduces testosterone production and therefore helps create a low-testosterone environment that can slow the progression of hormone-sensitive prostate cancer.
Leugard may be used alone or alongside other treatments depending on the stage of cancer and the treatment plan recommended by the oncologist.
Endometriosis is a condition in which tissue similar to the uterine lining grows outside the uterus. The tissue can respond to hormonal changes and may cause pelvic pain, painful periods and other symptoms.
By suppressing ovarian hormone production, Leuprorelin can reduce hormonal stimulation of endometriosis-related tissue and may help improve symptoms in appropriately selected patients.
Uterine fibroids are non-cancerous growths that can cause heavy menstrual bleeding, pelvic pressure and discomfort. Their growth can be influenced by estrogen and progesterone.
Leuprorelin can temporarily suppress ovarian hormone production, which may help reduce fibroid-related symptoms and, in some patients, reduce fibroid size.
In children with central precocious puberty, the reproductive hormone pathway becomes active earlier than expected. Leuprorelin can suppress this pathway and help slow premature sexual development.
This use requires specialist pediatric or endocrinology supervision and regular monitoring of growth and hormonal development.
Leugard is administered by a qualified healthcare professional according to the prescribed treatment schedule. The injection should not be self-administered unless specifically instructed and trained by an appropriate healthcare professional.
The exact injection technique and schedule depend on the specific Leugard formulation and the medical condition being treated.
Patients should attend all scheduled appointments so that their doctor can monitor treatment response and hormone levels when appropriate.
The dosage and treatment interval are determined by the doctor according to the patient's medical condition, age, hormone levels, treatment response and other clinical factors.
Do not change the treatment schedule, delay an injection or receive an additional injection without medical advice.
Because Leugard is a long-acting hormonal medicine, maintaining the prescribed injection schedule is important for consistent hormonal suppression.
Leugard may cause hot flashes, increased sweating, fatigue, decreased sexual desire, erectile difficulties, mood changes, injection-site reactions and muscle weakness in some patients.
Long-term treatment can reduce bone mineral density, which may increase the risk of osteoporosis or fractures. Your doctor may recommend appropriate monitoring and measures to support bone health.
Some patients may experience changes in blood sugar, cholesterol or cardiovascular risk factors during long-term hormonal therapy, so regular medical monitoring may be recommended.
Seek urgent medical attention for severe allergic reactions, chest pain, difficulty breathing, fainting, severe neurological symptoms or other serious unexpected symptoms.
Long-term suppression of sex hormones can reduce bone mineral density. Patients receiving prolonged treatment may need monitoring of bone health depending on their individual risk factors and treatment duration.
Your doctor may recommend adequate calcium and vitamin D intake, physical activity or other measures when appropriate. Do not start supplements without discussing them with your healthcare professional.
Leugard intentionally changes sex hormone levels. Men may experience reduced testosterone-related symptoms, while women may experience changes associated with reduced estrogen levels.
Hot flashes, sweating, changes in libido and mood changes can occur as hormone levels change. Discuss persistent or troublesome symptoms with your treating doctor.
Leugard should not be used during pregnancy unless specifically directed by a specialist in exceptional circumstances. Women who could become pregnant should discuss effective contraception with their healthcare professional during treatment.
If pregnancy occurs or is suspected during treatment, contact the treating healthcare professional promptly.
Breastfeeding patients should inform their doctor before receiving Leugard. The healthcare professional will determine whether treatment is appropriate and whether breastfeeding should be continued during therapy.
Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and supplements you use before receiving Leugard.
Particular attention may be required with medicines that affect heart rhythm, blood sugar, blood pressure or bone health. Your healthcare team can review your complete medication list before treatment.
If you miss a scheduled Leugard injection, contact your treating doctor or clinic as soon as possible to arrange the next dose.
Do not attempt to compensate for a missed injection by receiving an extra dose without medical advice. Maintaining the prescribed schedule is important for effective hormonal control.
Leugard 22.5mg Injection is a prescription hormonal medicine containing Leuprorelin 22.5mg. It is used for several hormone-sensitive conditions under specialist supervision.
Leugard may be used for hormone-dependent prostate cancer, endometriosis, uterine fibroids and certain cases of central precocious puberty.
Leugard 22.5mg contains Leuprorelin 22.5mg as its active ingredient.
Leugard is a hormonal therapy rather than a conventional cytotoxic chemotherapy medicine. It works by suppressing hormone production that can support certain hormone-sensitive cancers.
Leugard contains Leuprorelin, which initially stimulates and then suppresses the GnRH hormonal pathway. Continued treatment lowers sex hormone production.
Yes. Hot flashes and increased sweating are common effects of hormonal suppression and may occur during Leugard treatment.
Long-term hormonal suppression can reduce bone mineral density. Your doctor may monitor bone health and recommend appropriate preventive measures.
For additional healthcare information, visit our BuyCenforce website.
You can also browse other medicine categories available on our website, including Udenafil, Avanafil and Vardenafil.
For general medicine and health information, visit MedlinePlus.
This information is provided for general educational purposes and does not replace professional medical advice, diagnosis or treatment. Leugard 22.5mg Injection is a prescription medicine and should only be administered under the supervision of a qualified healthcare professional.
The appropriate treatment schedule, monitoring requirements and duration vary according to the patient's condition. Always follow the instructions provided by your treating doctor.
| Brand | Leugard |
| Manufacturer | Zydus Healthcare Limited |
| Composition | Leuprorelin 22.5mg |
| Package | 1 Vial |
| Ship time | 5-10 Business Days |
Free Shipping
For all oders over $99
Secure Payment
100% secure payment
24/7 Support
Online top support